ClinicalTrials.gg
CompletedNCT00957944Updated Oct 27, 2014Results posted

Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body

A Phase 1 interventional study of rotigotine transdermal patch (Neupro®) in Healthy Volunteers, sponsored by UCB Pharma. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-27.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of 2 rotigotine transdermal patches from 2 different manufacturing sites.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Rotigotine
  • Neupro®
03

In context

Lead sponsor

UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy, white, male volunteers between 18 and 55 years of age (inclusive)
  • between 19 and 28 kg/m² (inclusive)

Exclusion criteria

Exclusion Criteria:

  • previous participation in a clinical study with Rotigotine
  • history or current condition of epilepsy and/or seizures
  • known allergy or known/suspected clinically relevant drug
  • history of significant skin hypersensitivity to adhesives or other transdermal products or recently unresolved contact dermatitis
  • history or present condition of an atopic or eczematous dermatitis, psoriasis, and/or an active skin disease
  • clinically relevant abnormality in physical examination, , vital signs or safety laboratory examinations
  • positive , or C test or positive alcohol or drug test
  • relevant hepatic or renal dysfunction
  • intake of medication that might interfere with the test drug within 2 weeks prior to dosing
  • thickly hair-covered abdomen resulting in difficulties in finding appropriate patch application sites
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)

    Two single applications of rotigotine patches from two different manufacturing sites in the order A-B separated by a washout phase of at least 5 days

    Drug: rotigotine transdermal patch (Neupro®)

  • Experimental
    Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)

    Two single applications of rotigotine patches from two different manufacturing sites in the order B-A separated by a washout phase of at least 5 days

    Drug: rotigotine transdermal patch (Neupro®)

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-tz) of Unconjugated Rotigotine

    The AUC(0-tz) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration.

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  2. Cmax of Unconjugated Rotigotine

    The Cmax is the maximum plasma concentration.

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  3. AUC(0-∞) of Unconjugated Rotigotine

    The AUC(0-∞) is the area under the plasma concentration- time curve from zero up to infinity

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

Secondary outcomes

  1. AUC(0-tz) Norm (Apparent Dose) of Unconjugated Rotigotine

    The AUC(0-tz) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  2. AUC(0-tz) Norm (BW) of Unconjugated Rotigotine

    The AUC(0-tz) norm (BW) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  3. AUC(0-∞) Norm (Apparent Dose)

    The AUC(0-∞) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to infinity normalized by apparent dose (mg).

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  4. AUC(0-∞) Norm (BW)

    The AUC(0-∞) norm (BW) is the area under the plasma concentration- time curve from zero up to infinity normalized by body weight (kg).

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  5. Cmax,Norm (Apparent Dose) of Unconjugated Rotigotine

    The Cmax,norm (apparent dose) is the maximum plasma concentration normalized by apparent dose(mg).

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  6. Cmax,Norm (BW) of Unconjugated Rotigotine

    The Cmax,norm (BW) is the maximum plasma concentration normalized by body weight(kg).

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  7. Tmax of Unconjugated Rotigotine

    The tmax is the time to reach a maximum plasma concentration after patch application.

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  8. MRT of Unconjugated Rotigotine

    The MRT is the mean residence time.

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  9. λz of Unconjugated Rotigotine

    The λz is the rate constant of elimination.

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  10. t1/2 of Unconjugated Rotigotine

    The t1/2 is the terminal half- life.

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  11. CL/f of Unconjugated Rotigotine

    The CL/f is the apparent total body clearance.

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

  12. Apparent Dose

    Apparent dose of unconjugated rotigotine in mg. The apparent dose of unconjugated rotigotine was determined from the patches removed on Day 2.

    Time frame: 48 hours

07

Results

Posted Sep 22, 2010

Participant flow

A total of 40 healthy, male subjects has been randomized in order to complete the trial with at least 30 subjects eligible for the Pharmacokinetic Set (PKS). Baseline characteristics refer to the PKS.

First Intervention- 24 Hours
Participant flow — First Intervention- 24 Hours
MilestoneSequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)
Started2020
Completed2019
Not completed01
Withdrew: Withdrawal by subject01
Washout Period of at Least 5 Days
Participant flow — Washout Period of at Least 5 Days
MilestoneSequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)
Started2019
Completed2019
Not completed00
Second Intervention- 24 Hours
Participant flow — Second Intervention- 24 Hours
MilestoneSequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)
Started2019
Pharmacokinetic set (pks)2018
Completed2019
Not completed00

Outcome measures

PrimaryAUC(0-tz) of Unconjugated Rotigotine

The AUC(0-tz) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration.

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · (ng/ mL)*h
AUC(0-tz) of Unconjugated Rotigotine
(ng/ mL)*hTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
AUC(0-tz) of Unconjugated Rotigotine4.3899 ± 1.79594.4255 ± 2.3969
Statistical analysis
  • Treatment A (Test: PR 2.1.1 WCL) vs Treatment B (Reference: PR 2.1.1 AND) · ANOVA · Ratio of geometric ls- means: 1.0302 · 90% CI 0.9693 to 1.0951Bioequivalence is concluded if the 90% CIs for the ratio Treatment A/ Treatment B are fully included in the acceptance range from 0.8- 1.25 for AUC(0-tz), AUC(0-inf) and Cmax.
PrimaryCmax of Unconjugated Rotigotine

The Cmax is the maximum plasma concentration.

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · ng/ mL
Cmax of Unconjugated Rotigotine
ng/ mLTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
Cmax of Unconjugated Rotigotine0.21103 ± 0.088270.20386 ± 0.10194
Statistical analysis
  • Treatment A (Test: PR 2.1.1 WCL) vs Treatment B (Reference: PR 2.1.1 AND) · ANOVA · Ratio of geometric ls- means: 1.0571 · 90% CI 0.9903 to 1.1284Bioequivalence is concluded if the 90% CIs for the ratio Treatment A/ Treatment B are fully included in the acceptance range from 0.8- 1.25 for AUC(0-tz), AUC(0-inf) and Cmax.
PrimaryAUC(0-∞) of Unconjugated Rotigotine

The AUC(0-∞) is the area under the plasma concentration- time curve from zero up to infinity

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · (ng/ mL)*h
AUC(0-∞) of Unconjugated Rotigotine
(ng/ mL)*hTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
AUC(0-∞) of Unconjugated Rotigotine4.51237 ± 1.807094.55159 ± 2.42524
Statistical analysis
  • Treatment A (Test: PR 2.1.1 WCL) vs Treatment B (Reference: PR 2.1.1 AND) · ANOVA · Ratio of geometric ls- means: 1.0289 · 90% CI 0.9714 to 1.0899Bioequivalence is concluded if the 90% CIs for the ratio Treatment A/ Treatment B are fully included in the acceptance range from 0.8- 1.25 for AUC(0-tz), AUC(0-inf) and Cmax.
SecondaryAUC(0-tz) Norm (Apparent Dose) of Unconjugated Rotigotine

The AUC(0-tz) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · (ng/ mL)*(h/ mg)
AUC(0-tz) Norm (Apparent Dose) of Unconjugated Rotigotine
(ng/ mL)*(h/ mg)Treatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
AUC(0-tz) Norm (Apparent Dose) of Unconjugated Rotigotine2.23980 ± 0.710152.23035 ± 0.77992
SecondaryAUC(0-tz) Norm (BW) of Unconjugated Rotigotine

The AUC(0-tz) norm (BW) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · (ng/ mL)*h*kg
AUC(0-tz) Norm (BW) of Unconjugated Rotigotine
(ng/ mL)*h*kgTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
AUC(0-tz) Norm (BW) of Unconjugated Rotigotine364.930 ± 140.747367.452 ± 189.279
SecondaryAUC(0-∞) Norm (Apparent Dose)

The AUC(0-∞) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to infinity normalized by apparent dose (mg).

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · (ng/ mL)*(h/ mg)
AUC(0-∞) Norm (Apparent Dose)
(ng/ mL)*(h/ mg)Treatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
AUC(0-∞) Norm (Apparent Dose)2.30523 ± 0.711052.29747 ± 0.78191
SecondaryAUC(0-∞) Norm (BW)

The AUC(0-∞) norm (BW) is the area under the plasma concentration- time curve from zero up to infinity normalized by body weight (kg).

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · (ng/ mL)*h*kg
AUC(0-∞) Norm (BW)
(ng/ mL)*h*kgTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
AUC(0-∞) Norm (BW)375.224 ± 141.465378.003 ± 191.344
SecondaryCmax,Norm (Apparent Dose) of Unconjugated Rotigotine

The Cmax,norm (apparent dose) is the maximum plasma concentration normalized by apparent dose(mg).

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · (ng/ mL)/ mg
Cmax,Norm (Apparent Dose) of Unconjugated Rotigotine
(ng/ mL)/ mgTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
Cmax,Norm (Apparent Dose) of Unconjugated Rotigotine0.108148 ± 0.0376180.103965 ± 0.035474
SecondaryCmax,Norm (BW) of Unconjugated Rotigotine

The Cmax,norm (BW) is the maximum plasma concentration normalized by body weight(kg).

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · (ng/ mL) * kg
Cmax,Norm (BW) of Unconjugated Rotigotine
(ng/ mL) * kgTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
Cmax,Norm (BW) of Unconjugated Rotigotine17.6070 ± 7.264516.9748 ± 8.1930
SecondaryTmax of Unconjugated Rotigotine

The tmax is the time to reach a maximum plasma concentration after patch application.

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Median · hour (h)
Tmax of Unconjugated Rotigotine
hour (h)Treatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
Tmax of Unconjugated Rotigotine16.00 ± 4.9216.00 ± 5.12
SecondaryMRT of Unconjugated Rotigotine

The MRT is the mean residence time.

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · hour (h)
MRT of Unconjugated Rotigotine
hour (h)Treatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
MRT of Unconjugated Rotigotine19.914 ± 1.62019.980 ± 2.038
Secondaryλz of Unconjugated Rotigotine

The λz is the rate constant of elimination.

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · 1/ hour (1/h)
λz of Unconjugated Rotigotine
1/ hour (1/h)Treatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
λz of Unconjugated Rotigotine0.129745 ± 0.0262920.125217 ± 0.027732
Secondaryt1/2 of Unconjugated Rotigotine

The t1/2 is the terminal half- life.

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · hour (h)
t1/2 of Unconjugated Rotigotine
hour (h)Treatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
t1/2 of Unconjugated Rotigotine5.5408 ± 1.02055.7878 ± 1.1985
SecondaryCL/f of Unconjugated Rotigotine

The CL/f is the apparent total body clearance.

Time frame:
Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
Reported as:
Mean · L/h
CL/f of Unconjugated Rotigotine
L/hTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
CL/f of Unconjugated Rotigotine1185.98 ± 574.451227.56 ± 541.82
SecondaryApparent Dose

Apparent dose of unconjugated rotigotine in mg. The apparent dose of unconjugated rotigotine was determined from the patches removed on Day 2.

Time frame:
48 hours
Reported as:
Mean · mg
Apparent Dose
mgTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
Apparent Dose1.932 ± 0.3981.927 ± 0.489

Adverse events

Collected over Adverse Events (AEs) were collected up to 18 days from Day -1 (day before first dosing) to the Safety Follow- Up Visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A (Test: PR 2.1.1 WCL)—0/39 (0%)5/39 (12.8%)
Treatment B (Reference: PR 2.1.1 AND)—0/40 (0%)6/40 (15%)
Most frequent other events
Most frequent other events
EventTreatment A (Test: PR 2.1.1 WCL)Treatment B (Reference: PR 2.1.1 AND)
Application Site PruritusGeneral disorders4/393/40
FatigueGeneral disorders1/390/40
Hot FlushVascular disorders1/390/40
NauseaGastrointestinal disorders0/391/40
HeadacheNervous system disorders0/391/40
Sleep DisorderPsychiatric disorders0/391/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)Total
Mean37.0 ± 11.732.8 ± 7.235.0 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)Total
Female000
Male201838
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)Total
Hispanic or Latino000
Not Hispanic or Latino201838
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White201838
More than one race000
Unknown or Not Reported000
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)Total
Mean25.03 ± 2.1625.87 ± 1.7725.43 ± 2.00
Height
Height(meter (m))Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)Total
Mean1.82 ± 0.071.82 ± 0.081.82 ± 0.08
Weight
Weight(kilogram (kg))Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)Total
Mean83.18 ± 9.6285.33 ± 8.7584.20 ± 9.16
08

Study locations

1 site
  • Neuss, NRW, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2009
First posted
Aug 13, 2009
Start
Jul 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Sep 22, 2010
Last update
Oct 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00957944
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Aug 13, 2009
Start date
Jul 2009
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Sep 22, 2010
Last update
Oct 27, 2014

Study contacts

UCB Clinical Trial Call center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion